Skip to main content

Rydym wedi cadw rhai ffeiliau o'r enw cwcis ar eich dyfais. Y cwcis hyn yw:

  • Hanfodol ar gyfer y safle i weithio
  • Helpu i wella ein gwefan drwy gasglu ac adrodd gwybodaeth am sut rydych chi'n ei defnyddio

Hoffem hefyd arbed rhai cwcis i helpu i deilwra cyfathrebu.

BETA
Rydych yn edrych ar fersiwn wedi'i ddiweddaru o'r gwasanaeth hwn - bydd eich adborth yn ein helpu i'w wella.

Hysbysiad o Gontract

Cell Therapy Catapult GMP Manufacturing Partners.

  • Cyhoeddwyd gyntaf: 22 Mai 2014
  • Wedi'i addasu ddiwethaf: 22 Mai 2014

Nid yw'r prynwr yn defnyddio'r wefan hon i weinyddu'r hysbysiad.

I gofnodi eich diddordeb neu gael gwybodaeth neu ddogfennau ychwanegol, darllenwch y cyfarwyddiadau yn Nhestun Llawn yr Hysbysiad. (NODER: Nid oes angen ymateb i Hysbysiadau Dyfarnu Contractau a Hysbysiadau Gwybodaeth Ymlaen Llaw fel arfer)

Cynnwys

Crynodeb

OCID:
Cyhoeddwyd gan:
Cell & Gene Therapy Catapult
ID Awudurdod:
AA58950
Dyddiad cyhoeddi:
22 Mai 2014
Dyddiad Cau:
23 Mehefin 2014
Math o hysbysiad:
Hysbysiad o Gontract
Mae ganddo ddogfennau:
Nac Ydi
Wedi SPD:
Nac Ydi
Mae ganddo gynllun lleihau carbon:
AMH

Crynodeb

The Cell Therapy Catapult has recognised the need to engage with established Manufacturing Partners to leverage existing expertise across the Cell Therapy industry in its pursuit of the rapid development, delivery and commercialisation of cell therapies.

The Cell Therapy Catapult has internal activities for analytical, process development and manufacturing proving with its facilities on the 12th Floor of Guy's Hospital. It is desired to partner with centres of excellence for clinical manufacturing activities.

The Cell Therapy Catapult is engaged in numerous projects with an array of diverse products, and therefore wishes to engage in a framework agreement with several suppliers covering a wide range of skills and capabilities in order that these can be leveraged when required.

In order to fulfil its mission, the Cell Therapy Catapult needs to have access to sufficient manufacturing outsource providers to be able to confidently deliver on current and future projects across the entirety of the cell therapy industry. These projects could be internal Cell Therapy Catapult projects or those for which the Cell Therapy Catapult is acting on behalf of a client or partner. For this reason the Cell Therapy Catapult is looking to engage with outsource providers who may be able to offer one or more desired services in the following lots:

Lot 1: Immune cell therapy manufacture (including gene modified immune cell therapy).

Lot 2: Pluripotent derived cell therapy manufacture (iPS or hES).

Lot 3: MSC and other multi-potent cell therapy manufacture.

Lot 4: Other somatic cell therapy manufacture.

Lot 5: 3D culture based cell therapy manufacture.

To enable the manufacture in the specific lots the organisation should have experience, expertise and technology that includes the following activities where relevant to the particular lot:

— MHRA MIA(IMP) license for cell therapy applications (or equivalent local license outside of the UK);

— HTA license for donor material procurement testing (or equivalent local license outside of the UK);

— Hosting of GMP audits;

— Tech transfer support for incoming processes, including ability to absorb Catapult staff into the facility to aid tech transfer;

— Preparation of batch documentation;

— Manufacturing technologies and capability to enable processes may include but should not be limited to:

- Non-enclosed processing (using MBSCs within grade B background or isolators within grade C or grade D background);

- Enclosed processing (using closed systems in a grade C or grade D background);

- Adherent cell culture in T-flasks, cell factories and on microcarriers in bioreactors;

- Suspension culture of cells in static mode and in bioreactors;

- 3D culture of cells on surfaces;

- Cell separation;

- Cell activation;

- Differentiation;

- Volume reduction and washing of cells;

- Aseptic vial/bag filling;

- Product labelling;

- Cryopreservation;

— QC analytical testing of final products, in-process controls and raw materials;

— QA batch review;

— QP release of clinical material;

— Regular project meetings to report progress.

Testun llawn y rhybydd

HYSBYSIAD O GONTRACT - CYFNODOLYN SWYDDOGOL

Adran I: Awdurdod Contractio

I.1)

Enw, Cyfeiriad a Phwynt(iau) Cyswllt


Cell Therapy Catapult

12th Floor, Guy's Tower, Great Maze Pond

London

SE1 9RT

UK

Jodie Hill


ojeu@ct.catapult.org.uk


http://catapult.org.uk/celltherapy


Blwch wedi'i dicio
Blwch heb ei dicio
Blwch wedi'i dicio
Blwch heb ei dicio
Blwch wedi'i dicio
Blwch heb ei dicio

I.2)

Math o Awdurdod contractio a'i Brif Weithgaredd neu Weithgareddau

Blwch wedi'i dicio
Private Company Limited by Guarantee
Blwch heb ei dicio
Blwch heb ei dicio
Blwch heb ei dicio
Blwch heb ei dicio
Blwch heb ei dicio
Blwch heb ei dicio
Blwch heb ei dicio
Blwch heb ei dicio
Blwch heb ei dicio
Blwch heb ei dicio
Blwch wedi'i dicio
Cell Therapies
Na

Adran II: Amcan y Contract

II.1)

Disgrifiad

II.1.1)

Teitl a roddwyd i'r contract gan yr awdurdod contractio

Cell Therapy Catapult GMP Manufacturing Partners.

II.1.2(a))

Math o gontract gwaith

II.1.2(b))

Math o gontract cyflenwadau

II.1.2(c))

Math o gontract gwasanaeth

8

II.1.2)

Prif safle neu leoliad y gwaith, man cyflawni neu berfformio

UK.



UK

II.1.3)

Mae'r hysbysiad hwn yn ymwneud â

Blwch heb ei dicio
Blwch heb ei dicio
Blwch wedi'i dicio

II.1.4)

Gwybodaeth am gytundeb fframwaith (os yw'n berthnasol)

Blwch heb ei dicio
Blwch wedi'i dicio

Nifer y cyfranogwyr a ragwelir yn y cytundeb fframwaith

30

Hyd y cytundeb fframwaith

4

Cyfiawnhad dros gytundeb fframwaith sy'n para am fwy na phedair blynedd

Amcangyfrif o gyfanswm gwerth pryniannau yn ystod cyfnod llawn y cytundeb fframwaith

25 000 000GBP

Amlder a gwerth y contractau a gaiff eu dyfarnu

II.1.5)

Disgrifiad byr o'r contract neu'r pryniant/pryniannau

The Cell Therapy Catapult has recognised the need to engage with established Manufacturing Partners to leverage existing expertise across the Cell Therapy industry in its pursuit of the rapid development, delivery and commercialisation of cell therapies.

The Cell Therapy Catapult has internal activities for analytical, process development and manufacturing proving with its facilities on the 12th Floor of Guy's Hospital. It is desired to partner with centres of excellence for clinical manufacturing activities.

The Cell Therapy Catapult is engaged in numerous projects with an array of diverse products, and therefore wishes to engage in a framework agreement with several suppliers covering a wide range of skills and capabilities in order that these can be leveraged when required.

In order to fulfil its mission, the Cell Therapy Catapult needs to have access to sufficient manufacturing outsource providers to be able to confidently deliver on current and future projects across the entirety of the cell therapy industry. These projects could be internal Cell Therapy Catapult projects or those for which the Cell Therapy Catapult is acting on behalf of a client or partner. For this reason the Cell Therapy Catapult is looking to engage with outsource providers who may be able to offer one or more desired services in the following lots:

Lot 1: Immune cell therapy manufacture (including gene modified immune cell therapy).

Lot 2: Pluripotent derived cell therapy manufacture (iPS or hES).

Lot 3: MSC and other multi-potent cell therapy manufacture.

Lot 4: Other somatic cell therapy manufacture.

Lot 5: 3D culture based cell therapy manufacture.

To enable the manufacture in the specific lots the organisation should have experience, expertise and technology that includes the following activities where relevant to the particular lot:

— MHRA MIA(IMP) license for cell therapy applications (or equivalent local license outside of the UK);

— HTA license for donor material procurement testing (or equivalent local license outside of the UK);

— Hosting of GMP audits;

— Tech transfer support for incoming processes, including ability to absorb Catapult staff into the facility to aid tech transfer;

— Preparation of batch documentation;

— Manufacturing technologies and capability to enable processes may include but should not be limited to:

- Non-enclosed processing (using MBSCs within grade B background or isolators within grade C or grade D background);

- Enclosed processing (using closed systems in a grade C or grade D background);

- Adherent cell culture in T-flasks, cell factories and on microcarriers in bioreactors;

- Suspension culture of cells in static mode and in bioreactors;

- 3D culture of cells on surfaces;

- Cell separation;

- Cell activation;

- Differentiation;

- Volume reduction and washing of cells;

- Aseptic vial/bag filling;

- Product labelling;

- Cryopreservation;

— QC analytical testing of final products, in-process controls and raw materials;

— QA batch review;

— QP release of clinical material;

— Regular project meetings to report progress.

II.1.6)

Geirfa Gaffael Gyffredin (CPV)

33600000
71900000
73111000
73120000
33620000

II.1.7)

Contract wedi'i gwmpasu gan Gytundeb Caffael y Llywodraeth (GPA)

Blwch heb ei dicio

II.1.8)

Rhannu'n lotiau

Ie

Blwch heb ei dicio Blwch wedi'i dicio Blwch heb ei dicio

II.1.9)

A gaiff cynigion amrywiadol eu derbyn?

Ie

II.2)

Maint neu Gwmpas y Contract

II.2.1)

Cyfanswm maint neu gwmpas

The total estimated value of call offs under the framework is GBP 25,000,000.

25 000 000
GBP

II.2.2)

Opsiynau

Amserlen dros dro ar gyfer defnyddio'r opsiynau hyn

Nifer yr adnewyddiadau posibl

Yn achos contractau cyflenwadau neu wasanaethau adnewyddadwy, amserlen amcangyfrifedig ar gyfer contractau dilynol

II.3)

Hyd y contract neu derfyn amser ar gyfer ei gwblhau

48

Adran III: Gwybodaeth Gyfreithiol, Economaidd, Ariannol a Thechnegol

III.1)

Amodau sy'n Ymwneud â'r Contract

III.1.1)

Adneuon a gwarantau sydd eu hangen

Tenderers may be requested to sign a Parent Company Guarantee, depending on the evaluation of Financial Information.

III.1.2)

Prif Delerau ariannu a thalu a/neu gyfeiriad at y darpariaethau perthnasol

III.1.3)

Y ffurf gyfreithiol i'w chymryd gan y grŵp o gyflenwyr, contractwyr neu ddarparwyr gwasanaeth y caiff y contract ei ddyfarnu iddo

III.1.4)

Amodau penodol eraill y mae perfformiad y contract yn ddarostyngedig iddynt

Any conditions will be detailed in the tender documents.

III.2)

Amodau ar gyfer Cymryd Rhan

III.2.1)

Sefyllfa bersonol gweithredwyr economaidd, gan gynnwys gofynion sy'n ymwneud â chofrestru ar gofrestrau proffesiynol neu fasnach


Please see the PQQ.

III.2.2)

Capasiti economaidd ac ariannol


Please see the PQQ.



Please see the PQQ.


III.2.3)

Capasiti technegol


Please see the PQQ.



Please see the PQQ.


III.2.4)

Contractau sydd wedi'u cadw

Blwch heb ei dicio
Blwch heb ei dicio

III.3)

Amodau sy'n Benodol i Gontractau Gwasanaeth

III.3.1)

A gaiff y gwaith o ddarparu'r gwasanaeth ei gadw ar gyfer proffesiwn penodol?

Na

III.3.2)

A fydd yn ofynnol i endidau cyfreithiol nodi enwau a chymwysterau proffesiynol y personél a fydd yn gyfrifol am ddarparu'r gwasanaeth?

Na

Adran IV: Gweithdrefn

IV.1)

Math o Weithdrefn


Blwch heb ei dicio Blwch wedi'i dicio
Blwch heb ei dicio Blwch heb ei dicio
Blwch heb ei dicio Blwch heb ei dicio

Cyfiawnhad dros ddewis gweithdrefn gyflym

IV.1.1)

A yw ymgeiswyr wedi'u dewis eisoes?

Na

IV.1.2)

Cyfyngiadau ar nifer y gweithredwyr a gaiff eu gwahodd i dendro neu gymryd rhan

2548

Meini prawf gwrthrychol ar gyfer dewis nifer cyfyngedig o ymgeiswyr

Please see the PQQ.

IV.1.3)

Lleihau nifer y gweithredwyr yn ystod y broses negodi neu'r deialog

Blwch heb ei dicio

IV.2)

Meini Prawf Dyfarnu

Na


Ie

Na

IV.2.2)

Defnyddir arwerthiant electronig

Na

IV.3 Gwybodaeth Weinyddol

IV.3.1)

Rhif cyfeirnod a roddwyd i'r hysbysiad gan yr awdurdod contractio

CON-0038

IV.3.2)

Cyhoeddiad(au) blaenorol sy'n ymwneud â'r un contract

Blwch heb ei dicio
Blwch heb ei dicio


Cyhoeddiadau blaenorol eraill

IV.3.3)

Amodau ar gyfer cael manylebau a dogfennau ychwanegol

  23 - 06 - 2014   10:00

 


IV.3.4)

Terfyn amser ar gyfer derbyn tendrau neu geisiadau i gymryd rhan

  23 - 06 - 2014   10:00

IV.3.5)

Dyddiad yr anfonwyd y gwahoddiadau i dendro neu'r gwahoddiadau i gymryd rhan at ymgeiswyr a ddewiswyd


IV.3.6)

Yr iaith neu'r ieithoedd y gellir ei/eu defnyddio i lunio tendrau neu geisiadau i gymryd rhan

Blwch wedi'i dicio     

IV.3.7)

Isafswm y cyfnod y mae'n rhaid i'r cynigiwr gadw'r tendr 

IV.3.8)

Amodau ar gyfer agor tendrau





Adran VI: Gwybodaeth Arall

VI.1)

Nodwch a yw'r broses gaffael hon yn digwydd yn rheolaidd a rhowch Amcangyfrif o pryd y caiff hysbysiadau pellach eu cyhoeddi


VI.2)

A yw'r contract yn ymwneud â Phrosiect/Rhaglen a ariennir gan Gronfeydd Cymunedol?

Na



VI.3)

Gwybodaeth Ychwanegol

To express interest and request a copy of the PQQ please email ojeu@ct.catapult.org.uk

The deadline for completed PQQs is 23.6.2014 at 10:00 hours.

Prior to the deadline, Candidates will be able to attend a briefing session on the procurement process.

VI.4)

Gweithdrefnau ar gyfer apelio

VI.4.1)

Corff sy'n gyfrifol am y gweithdrefnau apelio










Corff sy'n gyfrifol am y gweithdrefnau cyfryngu










VI.4.2)

Cyflwyno apeliadau

VI.4.3)

Gwasanaeth y gellir cael gwybodaeth ynglŷn â chyflwyno apeliadau oddi wrtho


Cell Therapy Catapult





ojeu@ct.catapult.org.uk



VI.5)

Dyddiad yr anfonwyd yr Hysbysiad hwn

  20 - 05 - 2014

ATODIAD B

Gwybodaeth Am Lotiau

1     Immune cell therapy manufacture (including gene modified cell therapy)

1)

Disgrifiad Byr

2)

Geirfa Gaffael Gyffredin (CPV)

33600000
71900000
73111000
73120000
33620000

3)

Maint neu gwmpas


4)

Syniad o ddyddiadau gwahanol y contract

5)

Gwybodaeth Ychwanegol am lotiau

ATODIAD B

Gwybodaeth Am Lotiau

2     Pluripotent derived cell therapy manufacture (iPSC or hESC)

1)

Disgrifiad Byr

2)

Geirfa Gaffael Gyffredin (CPV)

33600000
71900000
73111000
73120000
33620000

3)

Maint neu gwmpas


4)

Syniad o ddyddiadau gwahanol y contract

5)

Gwybodaeth Ychwanegol am lotiau

ATODIAD B

Gwybodaeth Am Lotiau

3     MSC and other multi-potent cell therapy manufacture

1)

Disgrifiad Byr

2)

Geirfa Gaffael Gyffredin (CPV)

33600000
71900000
73111000
73120000
33620000

3)

Maint neu gwmpas


4)

Syniad o ddyddiadau gwahanol y contract

5)

Gwybodaeth Ychwanegol am lotiau

ATODIAD B

Gwybodaeth Am Lotiau

4     Other somatic cell therapy manufacture

1)

Disgrifiad Byr

2)

Geirfa Gaffael Gyffredin (CPV)

33600000
71900000
73111000
73120000
33620000

3)

Maint neu gwmpas


4)

Syniad o ddyddiadau gwahanol y contract

5)

Gwybodaeth Ychwanegol am lotiau

ATODIAD B

Gwybodaeth Am Lotiau

5     3D culture based cell therapy manufacture

1)

Disgrifiad Byr

2)

Geirfa Gaffael Gyffredin (CPV)

33600000
71900000
73111000
73120000
33620000

3)

Maint neu gwmpas


4)

Syniad o ddyddiadau gwahanol y contract

5)

Gwybodaeth Ychwanegol am lotiau


Codio

Categorïau nwyddau

ID Teitl Prif gategori
33600000 Cynhyrchion fferyllol Cyfarpar meddygol, deunydd fferyllol a chynhyrchion gofal personol
33620000 Cynhyrchion meddyginiaethol ar gyfer y gwaed, organau sy’n ffurfio gwaed a’r system gardiofasgwlaidd Cynhyrchion fferyllol
73120000 Gwasanaethau datblygu arbrofol Gwasanaethau datblygu ymchwil a datblygu arbrofol
71900000 Gwasanaethau labordy Gwasanaethau pensaernïol, adeiladu, peirianneg ac archwilio
73111000 Gwasanaethau labordy ymchwil Gwasanaethau ymchwil

Lleoliadau Dosbarthu

ID Disgrifiad
100 DU - I gyd

Cyfyngiadau Rhanbarthol ar y Rhybuddion

Mae’r prynwr wedi cyfyngu’r rhybuddion ar gyfer yr hysbysiad hwn i gyflenwyr yn y rhanbarthau canlynol.

ID Disgrifiad
Nid oes cyfyngiadau ar y rhybuddion ar gyfer yr hysbysiad hwn.

Ynglŷn â'r prynwr

Prif gyswllt:
ojeu@ct.catapult.org.uk
Cyswllt gweinyddol:
N/a
Cyswllt technegol:
N/a
Cyswllt arall:
N/a

Gwybodaeth bellach

Dyddiad Manylion
Nid oes unrhyw wybodaeth bellach wedi'i lanlwytho.

0800 222 9004

Mae'r llinellau ar agor rhwng 8:30am a 5pm o ddydd Llun i ddydd Gwener.

Rydym yn croesawu galwadau'n Gymraeg.

We welcome calls in Welsh.